Neumora Therapeutics Cuts 35% Workforce to Conserve Cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 15 2026
0mins
Source: stocktwits
- Drug Development Setback: Neumora Therapeutics' lead drug navacaprant failed to outperform placebo in two late-stage trials, causing shares to plummet nearly 47%, indicating a significant setback in the company's efforts in the depression treatment market and shaking investor confidence.
- Workforce Reduction: To conserve cash and refocus resources, the company plans to cut approximately 35% of its workforce, generating around $10 million in annual savings, a strategic move aimed at sustaining operations until the third quarter of 2027.
- Pipeline Outlook: Despite the disappointing results from navacaprant, Neumora remains optimistic about its remaining pipeline, including NMRA-511 for Alzheimer's agitation, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic conditions, with multiple clinical data readouts expected over the next 12 months.
- Market Sentiment: Despite the stock's sharp decline, retail sentiment on Stocktwits remains in the 'extremely bullish' territory, with seven out of nine analysts rating the stock as 'Buy' or higher, and a 12-month price target of $8.91 suggesting a potential upside of over 400%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NMRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NMRA
Wall Street analysts forecast NMRA stock price to rise
8 Analyst Rating
5 Buy
2 Hold
1 Sell
Moderate Buy
Current: 1.620
Low
3.00
Averages
9.33
High
18.00
Current: 1.620
Low
3.00
Averages
9.33
High
18.00
About NMRA
Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Neumora Therapeutics Faces Stock Collapse After Failed Trials
- Trial Failures Impact: Neumora Therapeutics' navacaprant failed to meet primary and key secondary endpoints in both the KOASTAL-2 and KOASTAL-3 Phase 3 trials, leading to immediate program discontinuation and a significant stock price collapse, reflecting extreme investor disappointment regarding the company's future prospects.
- Statistical Power Promise Broken: Despite the company's previous claims during the Q3 2024 earnings call that all three Phase 3 studies had approximately 90% statistical power, the final outcomes revealed a contrary trend, indicating a major misjudgment in trial design and expected success, which could further undermine investor confidence.
- Executive Statements Discrepancy: Following the KOASTAL-1 trial failure, Neumora executives characterized the results as an
See More
Neumora Therapeutics Shares Plunge Nearly 50% After Trial Failures
- Trial Failures: Neumora Therapeutics reported that navacaprant failed in both the KOASTAL-2 and KOASTAL-3 trials for major depressive disorder, resulting in a nearly 50% drop in stock price, significantly impacting investor value.
- Workforce Reduction: The company announced an immediate 35% workforce reduction, reflecting the financial strain and operational adjustments following the trial failures, which could hinder future R&D capabilities and market competitiveness.
- Investor Reaction: Following the disappointing trial results, shareholders are facing substantial losses, prompting law firm Levi & Korsinsky to investigate whether Neumora misled investors regarding its financial condition and the status of its clinical programs, potentially harming shareholder interests.
- Inconsistent Executive Statements: During the Q4 2025 earnings call in March 2026, COO Aurora expressed satisfaction with the progress of the navacaprant program but failed to mention the subsequent layoffs, indicating a disconnect between internal communications and external disclosures.
See More
Neumora Therapeutics Shares Plunge Nearly 50% After Trial Failures
- Trial Failures: Neumora Therapeutics reported that navacaprant failed in both Phase 3 KOASTAL-2 and KOASTAL-3 trials for major depressive disorder, resulting in a nearly 50% drop in stock price, significantly impacting shareholder value.
- Workforce Reduction: The company announced an immediate ~35% workforce reduction following the trial failures, highlighting the financial strain and uncertainty surrounding its future operations.
- Investor Reaction: The disappointing trial results have severely shaken investor confidence, prompting many shareholders to explore legal avenues to recover losses, indicating a pessimistic outlook on the company's future prospects.
- Inconsistent Management Statements: During the Q4 2025 earnings call in March 2026, COO Aurora expressed satisfaction with the progress of the navacaprant program but failed to mention the impending layoffs, revealing a lack of internal communication consistency.
See More
Neumora Therapeutics Cuts 35% Workforce to Conserve Cash
- Drug Development Setback: Neumora Therapeutics' lead drug navacaprant failed to outperform placebo in two late-stage trials, causing shares to plummet nearly 47%, indicating a significant setback in the company's efforts in the depression treatment market and shaking investor confidence.
- Workforce Reduction: To conserve cash and refocus resources, the company plans to cut approximately 35% of its workforce, generating around $10 million in annual savings, a strategic move aimed at sustaining operations until the third quarter of 2027.
- Pipeline Outlook: Despite the disappointing results from navacaprant, Neumora remains optimistic about its remaining pipeline, including NMRA-511 for Alzheimer's agitation, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic conditions, with multiple clinical data readouts expected over the next 12 months.
- Market Sentiment: Despite the stock's sharp decline, retail sentiment on Stocktwits remains in the 'extremely bullish' territory, with seven out of nine analysts rating the stock as 'Buy' or higher, and a 12-month price target of $8.91 suggesting a potential upside of over 400%.
See More
Neumora Discontinues Navacaprant Development for Depression
- Development Failure: Neumora Therapeutics announced that its navacaprant drug did not achieve statistical significance in the Phase 3 KOASTAL-2 and -3 studies for treating major depressive disorder, leading to the decision to discontinue its development, which directly impacts the company's future product pipeline and market competitiveness.
- Workforce Reduction: The company plans to reduce its workforce by approximately 35%, a move that not only reflects the financial pressure from the failed development but may also affect internal morale and future innovation capabilities, further weakening its position in the biopharmaceutical industry.
- Stock Price Decline: Following the announcement of the development failure, Neumora's stock price experienced a significant drop, undermining investor confidence and potentially leading more shareholders to seek legal recourse for losses, increasing the legal risks faced by the company.
- Legal Investigation: Holzer & Holzer, LLC is investigating whether Neumora violated federal securities laws, encouraging investors who suffered losses to contact legal counsel to protect their rights, highlighting potential compliance issues within the company.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Neumora Therapeutics Faces Stock Collapse After Failed Trials
- Trial Failures Impact: Neumora Therapeutics' navacaprant failed to meet primary and key secondary endpoints in both the KOASTAL-2 and KOASTAL-3 Phase 3 trials, leading to immediate program discontinuation and a significant stock price collapse, reflecting extreme investor disappointment regarding the company's future prospects.
- Statistical Power Promise Broken: Despite the company's previous claims during the Q3 2024 earnings call that all three Phase 3 studies had approximately 90% statistical power, the final outcomes revealed a contrary trend, indicating a major misjudgment in trial design and expected success, which could further undermine investor confidence.
- Executive Statements Discrepancy: Following the KOASTAL-1 trial failure, Neumora executives characterized the results as an
See More
Neumora Therapeutics Shares Plunge Nearly 50% After Trial Failures
- Trial Failures: Neumora Therapeutics reported that navacaprant failed in both the KOASTAL-2 and KOASTAL-3 trials for major depressive disorder, resulting in a nearly 50% drop in stock price, significantly impacting investor value.
- Workforce Reduction: The company announced an immediate 35% workforce reduction, reflecting the financial strain and operational adjustments following the trial failures, which could hinder future R&D capabilities and market competitiveness.
- Investor Reaction: Following the disappointing trial results, shareholders are facing substantial losses, prompting law firm Levi & Korsinsky to investigate whether Neumora misled investors regarding its financial condition and the status of its clinical programs, potentially harming shareholder interests.
- Inconsistent Executive Statements: During the Q4 2025 earnings call in March 2026, COO Aurora expressed satisfaction with the progress of the navacaprant program but failed to mention the subsequent layoffs, indicating a disconnect between internal communications and external disclosures.
See More
Neumora Therapeutics Shares Plunge Nearly 50% After Trial Failures
- Trial Failures: Neumora Therapeutics reported that navacaprant failed in both Phase 3 KOASTAL-2 and KOASTAL-3 trials for major depressive disorder, resulting in a nearly 50% drop in stock price, significantly impacting shareholder value.
- Workforce Reduction: The company announced an immediate ~35% workforce reduction following the trial failures, highlighting the financial strain and uncertainty surrounding its future operations.
- Investor Reaction: The disappointing trial results have severely shaken investor confidence, prompting many shareholders to explore legal avenues to recover losses, indicating a pessimistic outlook on the company's future prospects.
- Inconsistent Management Statements: During the Q4 2025 earnings call in March 2026, COO Aurora expressed satisfaction with the progress of the navacaprant program but failed to mention the impending layoffs, revealing a lack of internal communication consistency.
See More
Neumora Therapeutics Cuts 35% Workforce to Conserve Cash
- Drug Development Setback: Neumora Therapeutics' lead drug navacaprant failed to outperform placebo in two late-stage trials, causing shares to plummet nearly 47%, indicating a significant setback in the company's efforts in the depression treatment market and shaking investor confidence.
- Workforce Reduction: To conserve cash and refocus resources, the company plans to cut approximately 35% of its workforce, generating around $10 million in annual savings, a strategic move aimed at sustaining operations until the third quarter of 2027.
- Pipeline Outlook: Despite the disappointing results from navacaprant, Neumora remains optimistic about its remaining pipeline, including NMRA-511 for Alzheimer's agitation, NMRA-898 for schizophrenia, and NMRA-215 for cardiometabolic conditions, with multiple clinical data readouts expected over the next 12 months.
- Market Sentiment: Despite the stock's sharp decline, retail sentiment on Stocktwits remains in the 'extremely bullish' territory, with seven out of nine analysts rating the stock as 'Buy' or higher, and a 12-month price target of $8.91 suggesting a potential upside of over 400%.
See More
Neumora Discontinues Navacaprant Development for Depression
- Development Failure: Neumora Therapeutics announced that its navacaprant drug did not achieve statistical significance in the Phase 3 KOASTAL-2 and -3 studies for treating major depressive disorder, leading to the decision to discontinue its development, which directly impacts the company's future product pipeline and market competitiveness.
- Workforce Reduction: The company plans to reduce its workforce by approximately 35%, a move that not only reflects the financial pressure from the failed development but may also affect internal morale and future innovation capabilities, further weakening its position in the biopharmaceutical industry.
- Stock Price Decline: Following the announcement of the development failure, Neumora's stock price experienced a significant drop, undermining investor confidence and potentially leading more shareholders to seek legal recourse for losses, increasing the legal risks faced by the company.
- Legal Investigation: Holzer & Holzer, LLC is investigating whether Neumora violated federal securities laws, encouraging investors who suffered losses to contact legal counsel to protect their rights, highlighting potential compliance issues within the company.
See More
